12/03/2021 - General information
The head of Addictions Process at the Hospital del Mar Institute of Neuropsychiatry and Addictions (INAD) and coordinator of the Addictions research group at the Hospital del Mar Medical Research Institute has been recognised for her contribution to addictions research in Europe. Dr. Marta Torrens has be honoured with the EUFAS EAR 2020 Award, presented by theEuropean Federation of Addiction Societies and the journal European Addiction Research. This award recognises the work of the head of the INAD Addiction Process in terms of European research into addictions. The award has been presented since 2016 to figures who are outstanding in the field of addiction research. The awarding committee considered that the work of Dr. Torrens, with more than 200 high quality articles published in international journals, has made a substantial contribution to the advancement of translational research in this field, and has been instrumental in the introduction of various tools and scales for diagnosing and assessing dual pathology
21/03/2021 - General information
March 21st is World Down Syndrome Day and we are joining in by launching the "21 reasons to collaborate with science" campaign. The goal is to promote clinical research into people with Down's syndrome, to encourage them to get involved in the clinical studies that are currently being carried out and, in this way, to help improve the health and quality of life of these people. Through the 21 reasons campaign, the team of Dr. Rafael de la Torre, director of the Neurosciences research programme at the Hospital del Mar Medical Research Institute, wants to raise awareness and encourage people with Down syndrome to get involved in the studies they are conducting. According to Dr. de la Torre, "The therapeutic approach to these people, given their genetic features, has been quite specific, and the more knowledge we have, the more we will be able to adjust the therapy to their needs. Certain medical practices should also be studied in individuals with this syndrome."
21/03/2021 - General information
Down syndrome (DS) is the most common chromosomal abnormality in children leading to lifelong intellectual disability. Over one million people in the EU and US have DS, and its prevalence has increased in the last ten years. Thanks to significant advances in medical and social care, the life expectancy of individuals with DS has increased greatly, so that many of them reach even the age of 60-70. DS causes lifelong cognitive dysfunction, which results in important negative consequences for these individuals, their families and society. Despite the heavier social burden and the greater medical needs linked to this intellectual disability, there isn't an approved therapy for DS-related cognitive dysfunction yet. Furthermore, though there are specific cognitive screening tests designed for individuals with DS, no official guidelines have been developed to assess their cognitive deficits or their impact on quality of life of DS individuals and their families.
16/02/2021 - General information
Researchers of the Research Programme on Biomedical Informatics (GRIB) from UPF and Hospital del Mar Medical Research Institute (IMIM) have identified behavioural and linguistic changes in tweets in Spanish published by users suffering from depression and who are taking medication to treat this disease. Their work has been published in Journal of Medical Internet Research and was led by Ferran Sanz; with Angela Leis and Francesco Ronzano as first authors, who conducted the work together with Miguel Angel Mayer and Laura I Furlong, all from the Integrative Biomedical Informatics research group. Depression is one of the most widespread mental illnesses. According to the World Health Organization, it affects more than 322 million people of all ages and is one of the leading causes of disability worldwide.
10/02/2021 - General information
Only 30% of researchers in the world are women and about 30% of all students choose higher education in the field of science. In the case of the Hospital del Mar Medical Research Institute, 51% of researchers are women, but there is still a long way to go. Historically, the role of women in the field of science has been left in the background. With exceptions, the work of female scientists has been overlooked, ignored, or attributed to their male peers. This was reported by Matilda Joslyn Gage, the inspirer of the #NoMoreMatildas.campaign. But even today, the role of women in research still needs to be vindicated. IMIM and Hospital del Mar are once again promoting this 2021, marked by the COVID-19 pandemic, the #SheInspiredMe campaign, in which researchers, doctors and nurses explain which women have been their source. of inspiration to engage in research and to move forward. A vindication of female talent that we want to extend to everyone, encouraging you to record your own videos and post your photos using the hashtag #SheInspiredMe.
Més informació "International Day of Women and Girls in Science- February 11"
09/02/2021 - General information
Dr. Bigas has joined as Deputy Director of Preclinical Research at the Josep Carreras Institute, maintaining her relationship with the Hospital del Mar Medical Research Institute (IMIM), where she leads the Stem Cells and Cancer group. The new responsibility that Dr. Bigas assumes will serve to enhance coordination between all groups in the institute that do basic and translational research, seeking synergies between them and optimizing their research, as well as to enhance the existing collaboration between the professionals of our institute and those of the IMIM. In the last ten years, as head of the Stem Cells and Cancer group, she has studied the molecular and physiological processes of stem cells in different tissues, in order to draw similarities with the appearance and progression of cancerous processes. In particular, her research focuses on the study of hematopoietic stem cells, responsible for the formation of blood cells, in order to understand the process of leukemia and develop strategies to fight against this disease.Currently, her research group is working on the identification of epigenetic and gene expression profiles, which allow discovering new therapeutic targets not yet exploited clinically.
20/01/2021 - General information
The Journal of Clinical Investigation has published a review authored by Michelle von Locquenghien, Catalina Rozalén, and Toni Celià-Terrassa, all members of the Cancer Stem Cells & Metastasis Dynamics Lab at the Hospital del Mar Medical Research Institute (IMIM). In the article, they analyse current knowledge on the role of interferons -cytokines (proteins) involved in regulating the function of immune system cells- in the mechanisms that allow tumour cells to develop treatment resistance. The authors explain how the relationship between tumour cells and the immune system evolves as the cancer progresses, causing these cells to acquire systems that enable them to resist attack. They point out that the principal mechanisms used to achieve this are related to interferon signalling. In this respect, they highlight new evidence supporting immunotherapy-mediated immunoediting and show how interferons can impact either treatment response or resistance. All these factors lead the authors to support its potential as a therapeutic strategy in cancer.
Més informació "The role of interferons in tumour cell resistance to immunotherapy"
21/12/2020 - General information
The Codi Risc research project, coordinated by the IMIM Health Services research group and the Neuroscience research group from the Parc Taulí de Sabadell Hospital Consortium, is launching its new website and intranet. Codi Risc is a research project on the prevention of suicidal behaviour based on the Codi Risc Suïcidi (CRS) programme, which was created and implemented in Catalonia in 2014 by the Catalan Government's Department of Health. The purpose of the Codi Risc project is to study the frequency, as well as the epidemiological, clinical, neuropsychological, and biological risk factors involved in suicide attempts and repeated suicide attempts. It also covers the implementation, effectiveness, and costs of the Catalan Government's Codi Risc Suïcidi programme, as well as the development of personalised suicide risk prediction algorithms aimed at preventing suicidal behaviour.
Més informació "Codi RISC research project launches web and intranet"
03/12/2020 - General information
The Catalonian Antidoping Laboratory first obtained the ISO17025 accreditation 20 years ago, in November 2000. The laboratory has been accredited as an anti-doping laboratory since 1985 and is one of 30 laboratories in the world accredited by the World Anti-Doping Agency (WADA). The ISO17025 accreditation of all analytical procedures applied in doping controls was a prerequisite for maintaining doping accreditation from 2001 onwards. ISO17025 is an internationally recognised quality standard designed to guarantee the technical competence of testing laboratories, in other words, to ensure that laboratories deliver accurate, reliable results. In Spain, ISO17025 accreditation is awarded by ENAC (Entidad Nacional de Acreditación), a Spanish Government body.
Més informació "The Catalonian Antidoping Laboratory celebrates 20 years of ISO17025 accreditation."
30/11/2020 - General information
Dr. Dr. María Martínez, head of the neuro-oncology section of the Medical Oncology Service at Hospital del Mar and a researcher in the Cancer Molecular Therapy research group at the Hospital del Mar Medical Research Institute, will chair the Spanish Neuro-Oncology Research Group (Grupo Español de Investigación en Neurooncología; GEINO) for the next two years. Her appointment was confirmed on 27th November at the organisation's assembly, which was held virtually. Dr. Martínez explained that her objective at the head of GEINO is "To maintain and strengthen the execution of clinical trials in neuro-oncology, both for primary central nervous system tumours and brain metastases, and to continue down the same path as the previous chairmanship with regard to the most basic and translational researchers, as well as to build bridges and collaborate with other cooperative groups".
Més informació "Dr. María Martínez, new president of the Spanish Neuro-Oncology Research Group"
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
